Widely used:Recently Viewed
Clear All
$78 Mln
--
0.6
--
0
--
--
--
--
-24915493
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cidara Therapeutics (CDTX)
| 1,248.87 | -6.38 | -11.12 | 1,015.63 | 78.92 | 41.62 | -- |
|
BSE Sensex*
| 13.45 | 0.95 | 2.49 | 24.18 | 10.92 | 16.91 | 12.06 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Cidara Therapeutics (CDTX)
| 4.98 | -40.47 | -36.50 | -47.92 | 63.40 | -65.24 | -34.62 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$78.34 Mln
$39.07 Mln
$0.00 Mln
$164.37 Mln
$4.30 Mln
High
$0.59 - 24.40
7,038,240
NASDAQ: CDTX
San Diego, CA
https://www.cidara.com
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of... antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121 Read more
The total asset value of Cidara Therapeutics Inc (CDTX) stood at $ 213 Mln as on 30-Jun-24
The share price of Cidara Therapeutics Inc (CDTX) is $10.71 (NASDAQ) as of 08-Oct-2024 16:00 EDT. Cidara Therapeutics Inc (CDTX) has given a return of 78.92% in the last 3 years.
Cidara Therapeutics Inc (CDTX) has a market capitalisation of $ 78 Mln as on 08-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Cidara Therapeutics Inc (CDTX) is 0.60 times as on 08-Oct-2024, a 81% discount to its peers’ median range of 3.14 times.
Since, TTM earnings of Cidara Therapeutics Inc (CDTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cidara Therapeutics Inc (CDTX) and enter the required number of quantities and click on buy to purchase the shares of Cidara Therapeutics Inc (CDTX).
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121
The CEO & director of Dr. Jeffrey L. Stein Ph.D.. is Cidara Therapeutics Inc (CDTX), and CFO & Sr. VP is Dr. Jeffrey L. Stein Ph.D..
There is no promoter pledging in Cidara Therapeutics Inc (CDTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Cidara Therapeutics Inc. (CDTX) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-78.54
|
|
Net Margin(%)
|
-290.58
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cidara Therapeutics Inc (CDTX) was $0 Mln.
$-0.42
